Anti-HARS antibody - Aminoterminal end (ab71305)

Overview

  • Product nameAnti-HARS antibody - Aminoterminal end
    See all HARS primary antibodies
  • Description
    Rabbit polyclonal to HARS - Aminoterminal end
  • Tested applicationsSuitable for: ELISA, WB, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide corresponding to Human HARS (N terminal) conjugated to Keyhole Limpet Haemocyanin (KLH).

  • Positive control
    • K562 cell line lysates

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • Storage bufferPreservative: 0.09% Sodium Azide
    Constituents: PBS
  • Concentration information loading...
  • PurityAmmonium Sulphate Precipitation
  • Purification notesThis antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas

Associated products

Applications

Our Abpromise guarantee covers the use of ab71305 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA 1/1000.
WB 1/50 - 1/100. Predicted molecular weight: 56 kDa.
IHC-P 1/10 - 1/50.

Target

  • Tissue specificityBrain, heart, liver and kidney.
  • Involvement in diseaseDefects in HARS are a cause of Usher syndrome type 3B (USH3B) [MIM:614504]. USH3B is a syndrome characterized by progressive vision and hearing loss during early childhood. Some patients have the so-called 'Charles Bonnet syndrome,' involving decreased visual acuity and vivid visual hallucinations. USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH3 is characterized by postlingual, progressive hearing loss, variable vestibular dysfunction, and onset of retinitis pigmentosa symptoms, including nyctalopia, constriction of the visual fields, and loss of central visual acuity, usually by the second decade of life.
  • Sequence similaritiesBelongs to the class-II aminoacyl-tRNA synthetase family.
    Contains 1 WHEP-TRS domain.
  • Cellular localizationCytoplasm.
  • Information by UniProt
  • Database links
  • Alternative names
    • cytoplasmic antibody
    • EC 6.1.1.21 antibody
    • FLJ20491 antibody
    • HARS antibody
    • HisRS antibody
    • Histidine tRNA ligase, cytoplasmic antibody
    • histidine translase antibody
    • Histidine tRNA ligase antibody
    • Histidine--tRNA ligase antibody
    • Histidyl tRNA synthetase antibody
    • Histidyl-tRNA synthetase antibody
    • HRS antibody
    • Human histidyl tRNA synthetase homolog (HO3) mRNA complete cds antibody
    • SYHC_HUMAN antibody
    • USH3B antibody
    see all

Anti-HARS antibody - Aminoterminal end images

  • Anti-HARS antibody - Aminoterminal end (ab71305) at 1/60 dilution + K562 cell lysate at 35 µg

    Predicted band size : 56 kDa
    Observed band size : 55 kDa (why is the actual band size different from the predicted?)
  • ab71305 at 1/50 dilution staining HARS - Aminoterminal in human hepatocarcinoma tissue section by Immunohistochemistry (Formalin/ PFA fixed paraffin-embedded sections). A peroxidase conjugated secondary antibody was used followed by DAB staining.

References for Anti-HARS antibody - Aminoterminal end (ab71305)

ab71305 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab71305.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"